Trial Profile
A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Cilastatin (Primary)
- Indications Acute kidney injury; Cancer metastases; Sepsis
- Focus Adverse reactions
- Sponsors Arch Biopartners
- 18 Apr 2023 Results published in the Media Release
- 15 Jun 2020 Status changed from active, no longer recruiting to completed, according to an Arch Biopartners media release.
- 08 May 2020 According to a Arch Biopartners media release, A total of 40 out of 52 healthy, normal volunteers received Metablok during this trial.